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2015;56:5670–80.Bevacizumab or Dexamethasone
Implants for DME: 2-year Results
(The BEVORDEX Study)Both vascular endothelial growth factor inhibitors and steroids
given intravitreally have demonstrated superior visual acuity (VA)
beneﬁts to laser and/or sham for center-involving diabetic macular
edema (DME).1
The BEVORDEX study was the ﬁrst head-to-head randomized
clinical trial of bevacizumab versus a slow-release intravitreal
dexamethasone implant (DEX-implant; Ozurdex; Allergan Inc.,
Irvine, CA) for DME. This study was conducted in accordance
with the Declaration of Helsinki and was approved by local HumanResearch Ethics Committees. We previously reported the meth-
odology and the primary and 12-month secondary outcomes.2 At
12 months, we reported no difference between the groups in
proportion of eyes achieving the primary endpoint of a 10-letter
gain in VA. There was signiﬁcantly greater decrease in central
macular thickness with fewer intravitreal injections in the DEX-
implant group compared with the bevacizumab group at 12
months. However, a greater number of eyes in the DEX-implant
group lost vision, mainly owing to cataract.
Eyes continued in the trial for another year on the same treat-
ment allocation (i.e., bevacizumab every 4 weeks or DEX-implant
every 16 weeks, both as required). Sixty-eight of the 88 enrolled
eyes (77%) completed the 24-month trial. The CONSORT ﬂow-
sheet (Supplementary Fig 1, available at www.aaojournal.org)
shows that of the 20 eyes (from 13 patients) that exited the study
early, 10 had been assigned to DEX-implant and 10 to
bevacizumab.
The VA improvement seen at 12 months in both groups was
maintained at 24 months, with 20 of 46 DEX-implantetreated
eyes (43%) and 19 of 42 bevacizumab-treated eyes (45%)
achieving 10 letter VA gain (P ¼ 0.99). The proportion of
bevacizumab-treated eyes with a 10 letter VA gain was com-
parable with other trials of discontinuous anti-vascular endo-
thelial growth factor therapy in DME (e.g., Prospective
Randomized Trial of Intravitreal Bevacizumab or Laser Therapy
in the Management of Diabetic Macular Edema [BOLT] at 49%
and Diabetes Retinopathy Clinical Research Network Protocol I
at 49%). although baseline VA, inclusion criteria, and retreat-
ment strategies were different.3,4
The mean improvement in VA was 6.9 letters in DEX-
implante treated eyes (95% CI, 2.7e11.1) and 9.6 letters (95%
CI, 6.9e12.3) in bevacizumab-treated eyes (P ¼ 0.30; Fig 1A). At
baseline, 26 of 88 study eyes (29.5%) were pseudophakic; 10
randomized to bevacizumab and 16 to DEX-implant. In pseudo-
phakic eyes, the improvement in VA in DEX-implantetreated eyes
was similar to bevacizumab-treated eyes (Fig 1B). In phakic eyes,
there was a difference in mean VA change between the 2 treatment
groups between the 12- and 24-month time-points (Fig 1C), with
the DEX-implant group experiencing worse VA. This likely
represented development of cataract in the DEX-implant group
with subsequent improvement in vision by 24 months after cataract
surgery, with 11 of 30 DEX-implantetreated eyes (37%) and 2 of
32 bevacizumab-treated eyes (6%) undergoing cataract surgery
during the study. It is possible a larger study may have identiﬁed a
statistically signiﬁcant greater mean improvement in VA in favor
of bevacizumab in phakic eyes.
Although there was a signiﬁcantly greater reduction in central
macular thickness in the DEX-implant group at 12 months, the
graph of central macular thickness over time (Supplementary Fig 2,
available at www.aaojournal.org) shows that the bevacizumab
group gradually caught up so that there was no difference
between the groups at 24 months. This pattern was also reﬂected
in regression of hard exudates from the foveal center.5
Eyes randomized to receive bevacizumab received more
injections (mean; 9.1; median, 9.0; SD, 3.1) than those ran-
domized to the DEX-implant (mean, 2.8; median, 3.0; SD, 0.9)
during the ﬁrst 12 months of treatment. However, the difference
was less pronounced in the second year of treatment, with the
mean number bevacizumab injections being 4.8 (median, 2.0;
SD, 5.1) compared with 2.2 (median, 2.0; SD, 1.2) DEX-implant1399
Figure 1. Mean visual acuity (VA) according to treatment type from baseline to 24 months. Mean VA was recorded every 4 weeks and standard error bars
are included for (A) all eyes entering the trial, (B) eyes that were pseudophakic on entering the study (the mean improvement in VA was 8.9 letters [95%
CI, 2.0e13.4] for those treated with the dexamethasone implant and 7.7 letters [95% CI, 3.03e14.8] for those treated with bevacizumab; P¼ 0.77), (C) eyes
that were phakic on entering the study (the mean improvement in VA was 5.8 letters [95% CI, 0.07e11.5] for those treated with the dexamethasone
implant and 10.2 letters [95% CI, 7.17e13.3] for those treated with bevacizumab; P ¼ 0.19).
Ophthalmology Volume 123, Number 6, June 2016injections. Over 2 years, the number of bevacizumab intravitreal
injections was comparable with the number of ranibizumab in-
jections in the deferred laser cohort of Diabetes Retinopathy
Clinical Research Network Protocol I.4 The 5-year results from
the Diabetes Retinopathy Clinical Research Network Protocol
I trial reported a signiﬁcant decrease in the number of ranibi-
zumab injections required for DME in years 3 through 5, so
the difference in treatment load may be less signiﬁcant after
2 years of intensive anti-vascular endothelial growth factor
therapy.1
One bevacizumab-treated eye lost 10 letters, whereas 5 of 46
DEX-implantetreated eyes had this degree of vision loss. In 2 eyes
in the DEX-implant group and 1 eye in the bevacizumab group
with a history of laser-treated proliferative diabetic retinopathy,
neovascularization developed after cataract surgery. There was 1
patient with undiagnosed syphilis who developed acute posterior
placoid chorioretinopathy after receiving a DEX-implant to that
eye.2 There were no cases of endophthalmitis or retinal
detachment. There was no new systemic safety signal.
As expected, DEX-implantetreated eyes had higher rates of
increased intraocular pressure. An increase in intraocular pressure
by 5 mmHg from baseline at any visit, occurred in 34 of 46
DEX-implantetreated eyes (74%) and 20 of 42 bevacizumab-
treated eyes (48%), with 10 of 46 DEX-implantetreated eyes1400(22%) requiring the addition of topical ocular hypotensives,
whereas no bevacizumab-treated eyes required this. Remem-
bering eyes with advanced or uncontrolled glaucoma were
excluded from entry, no study eye underwent incisional glaucoma
drainage surgery similar to the low rates seen in other trials of
Ozurdex in DME (0.6% in the MEAD trial and 0% in the
PLACID trial).1
A strength of this study was the opportunity to use the
DEX-implant every 16 weeks. Previous industry-sponsored studies
have failed to reach predeﬁned primary endpoints because of the
mistaken belief that the DEX-implant usually has a therapeutic
effect lasting 6 months.1
In conclusion, the 24-month results of the BEVORDEX study
identiﬁed no signiﬁcant difference in the primary endpoint of
proportion of eyes with a 10-letter gain in VA between bev-
acizumab and DEX-implant treatment, with both agents providing
good improvements. The burden of injections was signiﬁcantly
greater with bevacizumab. However, the DEX-implant group had
more cases of visual loss, mainly in eyes that were phakic at
baseline. Elevated intraocular pressure in the DEX-implant group
could largely be managed with topical therapy. Therefore, the
DEX-implant could be considered a second-line treatment option
in phakic patients with DME, whereas potentially a ﬁrst-line
treatment option in pseudophakic patients.
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Receptor-InteractingProtein-Like 1
in Cancer-Associated
RetinopathyParaneoplastic syndromes constitute symptoms from organs distant
from a malignant neoplasm present in the body, and are in many
cases mediated by immune cross-reactivity between the neoplasm
and normal host tissue. Cancer-associated retinopathies (CAR) are
rare retinal disorders associated with autoantibodies directed to
various retinal antigens. The immune response initially arises to
suppress a tumor growth, ultimately resulting in rapid, bilateral,
and painless loss of vision.1 If a subsequent clinical investigation
reveals an underlying malignancy, the retinal damage is
categorized as a paraneoplastic syndrome.2
We report on the identiﬁcation of aryl hydrocarbon receptor
interacting protein-like 1 (AIPL1), a retinal and pineal glande
speciﬁc protein, as the autoantigen in a patient with CAR and ma-
lignant osteosarcoma. The study was performed in accordance with
the Declaration of Helsinki and ethics committee approval was ob-
tained (application number UP02-415). The patient was a previously
healthy 13-year-old girl without any family history of autoimmunity
or ophthalmic disorders. She suffered from pain of varying intensity
in her right heel with simultaneous progressive photosensitivity and
bilateral gradually increasing visual loss. Ophthalmologic exami-
nations revealed a rapid decline in visual acuity over 3 months, from
1.0 to 0.2 in the left eye, and from 0.8 to 0 in the right eye. Optical
coherence tomography showed a thinning of retinal layers, indi-
cating retinal atrophy (Fig 1A, available at www.aaojournal.org).
Full-ﬁeld electroretinogram demonstrated a reduction of rodecone
function with >90% compared with the response some months
before the patient developed blindness (Fig 1B). At the age of 15, two
years after the onset of symptoms of visual loss, her vision had
deteriorated to a stage at which she only could distinguish between
dark and light. Owing to the severity of the visual loss, the initial
medical attention was focused on the eyes. Eventually, the
patient’s pain in the heel was investigated and routine skeletal x-
ray examination of the foot did not show any abnormality (Fig 2A,
left). However, magnetic resonance imaging indicated an
edematous tumor in right calcaneus (Fig 2A, right). Biopsy of the
calcaneus and cytological examination after decalciﬁcation
revealed a small cell tumor (Fig 2B). Because the tumor cells did
not show typical chromosomal abnormalities seen in Ewing
sarcoma, the tumor was classiﬁed as osteosarcoma. Using a serum
sample from the patient, a healthy control, and an anti-AIPL1 anti-
body, human retinal tissue was immunostained. Using the CAR
serum, this revealed a strong staining of the synaptic region of the
photoreceptor cells, with an overlap with anti-AIPL1 antibody
staining. A similar staining pattern was not seen with serum from a
healthy control (Fig 2C-E).1401
